[New possibilities of targeted therapy in the treatment of hepatocellular carcinoma with the help of molecular biology]

Orv Hetil. 2010 Oct 24;151(43):1763-8. Review.
Hagymási K, Tulassay Z.
Orv Hetil. 2010 Oct 24;151(43):1763-8. Review.
I composti retinoidi, l'inibizione del ciclo cellulare e la terapia proteosomica ed epigeneticia possono essere altri potenziali bersagli promettenti nel carcinoma epatocellulare (HCC).
Retinoidi/carcinoma epatocellulare

Hepatocellular carcinoma (HCC) has a poor prognosis. Approximately 85% of patients are not candidates for curative treatments at the time of diagnosis; hence palliative modalities (transcatheter arterial chemoembolisation, radiofrequency ablation, systemic chemotherapy) are used. Systemic chemotherapies have disappointing results. The increasing knowledge in the molecular biology of HCC will increase the possibilities of targeted therapy. The multi-tyrosine kinase inhibitor sorafenib is the only drug which has approved. The VEGF-inhibitors (bevacizumab, sunitinib), EGFR-blocker agents (erlotinib), as well as the inhibition of mTOR (rapamycin) are promising. Combination of sorafenib or other anti-angiogenic agents with local ablative procedure (transcatheter arterial chemoembolisation, radiofrequency ablation), or with curative hepatectomy also can be favorable. Alteration of Wnt pathway, retinoid compounds, inhibition of the cell cycle as well as the proteosome, and epigenetic therapy can be other potential promising targets in HCC.